Molecular mechanisms regulating the angiogenic phenotype in tumors: Clinical impact in the future

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3111-3119

  Aubry, Karine ^a   Barriere, Guilaine ^a   Chable Rabinovitch, Helene ^a   Dutour, Aurelie ^a   Paraf, Francois ^a   Monteil, Jacques ^a   Rigaud, Michel ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenesis; Cancer dormancy; Circulating cells; Endostatin; Review

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOSTATIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; ENDOSTATIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; METALLOPROTEINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TUMSTATIN; VASCULOTROPIN;

ACCESSORY CELL; ANGIOGENESIS; BLOOD VESSEL; CANCER THERAPY; CYTOGENETICS; ENDOTHELIUM CELL; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE;

EID: 35348980203     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573, 1889.
2. Cleaver O and Melton DA: Endothelial signaling during development. Nat Med 9(6): 661-668, 2003.
3. Majno G and Joris I: Endothelium 1977: a review. Adv Exp Med Biol 104: 169-225, 481-526, 1978.
4. Pasqualini R, Arap W and McDonald DM: Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 8(12): 563-571, 2002.
5. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weaving LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ and Pasqualini R: Steps toward mapping the human vasculature by phage display. Nat Med 8(2): 121-127, 2002.
6. Magder S, Neculcea J, Neculcea V and Sladek R: Lipopolysaccharide and TNF-alpha produce very similar changes in gene expression in human endothelial cells. J Vasc Res 43(5): 447-461, 2006.
7. Garcia-Vallejo JJ, Van Dijk W, Van Het Hof B, Van Die I, Engelse MA, Van Hinsbergh VW and Gringhuis SI: Activation of human endothelial cells by tumor necrosis factor-alpha results in profound changes in the expression of glycosylation-related genes. J Cell Physiol 206(1): 203-210, 2006.
8. Schultheiss C, Blechert B, Gaertner FC, Drecoll E, Mueller J, Weber GF, Drzezga A and Essler M: In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis 9(2): 59-65, 2006.
9. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13(1): 31-36, 1991.
10. Hida K and Klagsbrun M: A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65(7): 2507-2510, 2005.
11. Bertolini F, Shaked Y, Mancuso P and Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6(11): 835-845, 2006.
12. Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175-203, 1985.
13. Rumpold H, Wolf D, Koeck R and Gunsilius E: Endothelial progenitor cells: a source for therapeutic vasculogenesis? J Cell Mol Med 8(4): 509-518, 2004.
14. Dignat-George F and Sampol J: Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol 65(4): 215-220, 2000.
15. Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M and Dignat-George F: Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 4(3): 671-677, 2006.
16. Goon PK, Boos CJ, Stonelake PS, Blann AD and Lip GY: Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb Haemost 96(1): 45-52, 2006.
17. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J and Heymach JV: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11(9): 3514-3522, 2005.
18. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, Martinelli G and Bertolini F: Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 61(11): 4341-4344, 2001.
19. Arbab AS, Pandit SD, Anderson SA, Yocum GT, Bur M, Frenkel V, Khuu HM, Read EJ and Frank JA: Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells 24(3): 671-678, 2006.
20. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R and Keshet E: VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1): 175-189, 2006.
21. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD and McDonald DM: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116(10): 2610-2621, 2006.
22. Bergers G, Song S, Meyer-Morse N, Bergsland E and Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111(9): 1287-1295, 2003.
23. Harper J and Moses MA: Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. Exs 96: 223-268, 2006.
24. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658): 404-407, 1997.
25. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2): 277-285, 1997.
26. Oh SP, Kamagata Y, Muragaki Y, Timmons S, Ooshima A and Olsen BR: Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA 91(10): 4229-4233, 1994.
27. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L and Huber PE: Endostatin's antiangiogenic signaling network. Mol Cell 13(5): 649-663, 2004.
28. Benezra R, Davis RL, Lockshon D, Turner DL and Weintraub H: The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61(1): 49-59, 1990.
29. Jiang BH, Agani F, Passaniti A and Semenza GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57(23): 5328-5335, 1997.
30. McBride JL and Ruiz JC: Ephrin-A1 is expressed at sites of vascular development in the mouse. Mech Dev 77(2): 201-204, 1998.
31. Cheng N and Chen J: Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism. J Biol Chem 276(17): 13771-13777, 2001.
32. Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl: S81-96, 2002.
33. Ma L, del Soldato P and Wallace JL: Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci USA 99(20): 13243-13247, 2002.
34. El-Aneed A: Current strategies in cancer gene therapy. Eur J Pharmacol 498(1-3): 1-8, 2004.
35. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K and Dellian M: Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 9(6): 2335-2341, 2003.
36. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D and McDonald DM: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101(7): 1401-1413, 1998.
37. Dutour A, Monteil J, Paraf F, Charissoux JL, Kaletta C, Sauer B, Naujoks K and Rigaud M: Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 11(2): 311-319, 2005.
38. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K and Dellian M: Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 105(4): 561-567, 2003.
39. Lappalainen K, Miettinen R, Kellokoski J, Jaaskelainen I and Syrjanen S: Intracellular distribution of oligonucleotides delivered by cationic liposomes: light and electron microscopic study. J Histochem Cytochem 45(2): 265-274, 1997.
40. McLean JW, Fox EA, Baluk P, Bolton PB, Haskell A, Pearlman R, Thurston G, Umemoto EY and McDonald DM: Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol 273(1 Pt 2): H387-404, 1997.
41. Simionescu M, Simionescu N and Palade GE: Partial chemical characterization of the anionic sites in the basal lamina of fenestrated capillaries. Microvasc Res 28(3): 352-267, 1984.
42. Vink H and Duling BR: Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 79(3): 581-589, 1996.
43. Ran S, Downes A and Thorpe PE: Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62(21): 6132-6140, 2002.
44. Liu L, Sanz S, Heggestad AD, Antharam V, Notterpek L and Fletcher BS: Endothelial targeting of the Sleeping Beauty transposon within lung. Mol Ther 10(1): 97-105, 2004.
45. Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, Scappaticci FA, Saplis RJ, Ekker SC, Low WC, Freese AB and Largaespada DA: Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 12(5): 778-788, 2005.
46. Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL and Griffioen AW: Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun 349(3): 1073-1078, 2006.
47. Gupta SK, Hassel T and Singh JP: A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 92(17): 7799-7803, 1995.
48. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA and Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87(17): 6624-6628, 1990.
49. Luster AD, Greenberg SM and Leder P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182(1): 219-231, 1995.
50. O'Reilly MS, Holmgren L, Shinq Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2): 315-328, 1994.
51. Pike SE, Yao L, Jones KD, Cherney B, Apella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G and Tosato G: Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188(12): 2349-2356, 1998.
52. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE and Kalluri R: Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275(28): 21340-21348, 2000.
53. van der Schaft DW, Toebes EA, Haseman JR, Mayo KH and Griffioen AW: Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 96(1): 176-181, 2000.
54. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F and Griffioen AW: Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103(43): 15975-15980, 2006.
55. Scott K and Weinberg C: Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J 19(7-9): 467-477, 2004.
56. Andre S, Maljaars CE, Halkes KM, Gabius HJ and Kamerling JP: Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett 17(3): 793-798, 2007.
57. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9(2): 267-285, 2005.
58. Maekawa R, Maki H, Yoshida H, Hojo K, Tanaka H, Wada T, Uchida N, Takeda Y, Kasai H, Okamoto H, Tsuzuki H, Kambayashi Y, Watanabe F, Kawada K, Toda K, Ohtani M, Sugita K and Yoshioka T: Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res 59(6): 1231-1235, 1999.
59. Jiang Y, Goldberg ID and Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21(14): 2245-2252, 2002.
60. Steeghs N, Nortier JW and Gelderblom H: Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 14(2): 942-953, 2007.
61. Pierschbacher MD and Ruoslahti E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309(5963): 30-33, 1984.
62. Lawler J, Weinstein R and Hynes RO: Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol 107(6 Pt 1): 2351-2361, 1988.
63. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR and Kleinman HK: Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58(5): 933-943, 1989.
64. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL and Kessler H: N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42(16): 3033-3040, 1999.
65. Duggan ME, Duong LT, Fisher JE, Hamill TG, Hoffman WF, Huff JR, Ihle NC, Leu CT, Nagy RM, Perkins JJ, Rodan SB, Wesolowski G, Whitman DB, Zartman AE, Rodan GA and Hartman GD: Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist. J Med Chem 43(20): 3736-3745, 2000.
66. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA and Schwaiger M: Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46(8): 1333-1341, 2005.
67. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3): 353-364, 1996.
68. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339(6219): 58-61, 1989.